Cigna Corporation (CI) – Evernorth’s long term opportunity

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Cigna Corporation (CI) (Q1FY23)

Highlights

Cigna Corporation Healthcare has launched a copay assurance plan aimed at limiting out-of-pocket costs for customers in their prescription drug benefits. The plan sets maximum copayments at $5 for generic drugs, $25 for preferred brand medications, and $45for preferred specialty medications.

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– Segment Performance
– Key Metrics

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 33

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates